These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34917942)

  • 21. Occurrence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline.
    Tuckman M; Petersen PJ; Howe AY; Orlowski M; Mullen S; Chan K; Bradford PA; Jones CH
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3205-11. PubMed ID: 17620376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
    Morfin-Otero R; Noriega ER; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
    Petersen PJ; Jacobus NV; Weiss WJ; Sum PE; Testa RT
    Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli.
    Zhang Y; Zhao C; Wang Q; Wang X; Chen H; Li H; Zhang F; Wang H
    J Antimicrob Chemother; 2020 Sep; 75(9):2609-2615. PubMed ID: 32591806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study.
    Seifert H; Blondeau J; Dowzicky MJ
    Int J Antimicrob Agents; 2018 Oct; 52(4):474-484. PubMed ID: 30012439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
    Decousser JW; Woerther PL; Soussy CJ; Fines-Guyon M; Dowzicky MJ
    Antimicrob Resist Infect Control; 2018; 7():68. PubMed ID: 29876099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries.
    Ko KS; Song JH; Lee MY; Park S; Kwon KT; Heo ST; Ryu SY; Oh WS; Peck KR; Lee NY
    Diagn Microbiol Infect Dis; 2006 Aug; 55(4):337-41. PubMed ID: 16631337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline.
    Macone AB; Caruso BK; Leahy RG; Donatelli J; Weir S; Draper MP; Tanaka SK; Levy SB
    Antimicrob Agents Chemother; 2014; 58(2):1127-35. PubMed ID: 24295985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic and genotypic characteristics of tetracycline resistant Acinetobacter baumannii isolates from nosocomial infections at Tehran hospitals.
    Maleki MH; Sekawi Z; Soroush S; Azizi-Jalilian F; Asadollahi K; Mohammadi S; Emaneini M; Taherikalani M
    Iran J Basic Med Sci; 2014 Jan; 17(1):21-6. PubMed ID: 24592303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014.
    Marco F; Dowzicky MJ
    J Glob Antimicrob Resist; 2016 Sep; 6():50-56. PubMed ID: 27530839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014).
    Sader HS; Castanheira M; Farrell DJ; Flamm RK; Mendes RE; Jones RN
    Int J Antimicrob Agents; 2016 Aug; 48(2):144-50. PubMed ID: 27291285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of
    Chiu SK; Huang LY; Chen H; Tsai YK; Liou CH; Lin JC; Siu LK; Chang FY; Yeh KM
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
    Huband MD; Castanheira M; Farrell DJ; Flamm RK; Jones RN; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2016 Jun; 47(6):495-9. PubMed ID: 27211209
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    García-Castillo M; Hernández-García M; Correa A; Coppi M; Griener T; Fritsche T; Pitart C; Sampaio J; Seifert H; Wake K; Wootton M; Vila J; Cantón R
    JAC Antimicrob Resist; 2024 Jun; 6(3):dlae088. PubMed ID: 38872714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints.
    Papaparaskevas J; Tzouvelekis LS; Tsakris A; Pittaras TE; Legakis NJ;
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):187-94. PubMed ID: 19836184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z; Chen M; Yu Y; Pan S; Liu Y
    Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.